Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

C4 Therapeutics Inc (CCCC)

C4 Therapeutics Inc (CCCC)
1.3100 -0.0650 (-4.73%) 04/04/25 [NASDAQ]
1.1000 x 100 1.4700 x 2,000
Realtime by (Cboe BZX)
1.1000 x 100 1.4700 x 2,000
Realtime 1.3800 +0.0700 (+5.34%) 05:09 ET
Quote Overview for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.2700
Day High
1.3700
Open 1.3500
Previous Close 1.3750 1.3750
Volume 1,125,200 1,125,200
Avg Vol 818,380 818,380
Stochastic %K 6.73% 6.73%
Weighted Alpha -85.00 -85.00
5-Day Change -0.4400 (-25.14%) -0.4400 (-25.14%)
52-Week Range 1.2700 - 8.0800 1.2700 - 8.0800
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 92,997
  • Shares Outstanding, K 70,990
  • Annual Sales, $ 35,580 K
  • Annual Income, $ -105,320 K
  • EBIT $ -120 M
  • EBITDA $ -123 M
  • 60-Month Beta 3.11
  • Price/Sales 2.74
  • Price/Cash Flow N/A
  • Price/Book 0.45

Options Overview Details

View History
  • Implied Volatility 533.10% ( +7.29%)
  • Historical Volatility 87.59%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 533.10% on 04/04/25
  • IV Low 8.04% on 07/12/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 24
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 1,509
  • Open Int (30-Day) 1,483

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.51
  • Number of Estimates 4
  • High Estimate -0.31
  • Low Estimate -0.60
  • Prior Year -0.41
  • Growth Rate Est. (year over year) -24.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2700 +3.15%
on 04/04/25
Period Open: 2.3800
2.4501 -46.53%
on 03/05/25
-1.0700 (-44.96%)
since 03/04/25
3-Month
1.2700 +3.15%
on 04/04/25
Period Open: 3.9200
4.2600 -69.25%
on 01/06/25
-2.6100 (-66.58%)
since 01/03/25
52-Week
1.2700 +3.15%
on 04/04/25
Period Open: 7.7200
8.0800 -83.79%
on 04/12/24
-6.4100 (-83.03%)
since 04/04/24

Most Recent Stories

More News
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

CCCC : 1.3100 (-4.73%)
C4 Therapeutics to Participate in Upcoming March Investor Conferences

CCCC : 1.3100 (-4.73%)
Investors Eye Biotech Stocks as Cancer Therapies Take Center Stage in 2025

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As the new year begins, the American Association for Cancer Research (AACR) has highlighted expert predictions...

ONCY : 0.4952 (-3.28%)
TYRA : 7.74 (-6.75%)
ZNTL : 1.1700 (-8.95%)
ONC.TO : 0.70 (-1.41%)
CMPX : 1.4600 (-9.03%)
CCCC : 1.3100 (-4.73%)
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology

CCCC : 1.3100 (-4.73%)
C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CCCC : 1.3100 (-4.73%)
C4 Therapeutics Reports Promising Phase 1 Clinical Trial Results for Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at ASH Annual Meeting

Cemsidomide shows promising response rates in multiple myeloma and non-Hodgkin's lymphoma, with manageable safety profiles.Quiver AI SummaryC4 Therapeutics, Inc. presented promising clinical data at the...

CCCC : 1.3100 (-4.73%)
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

CCCC : 1.3100 (-4.73%)
Unusual Options Activity: Strategies for Success with Three Single-Letter Stocks

Hidden within Wednesday’s 1,211 unusually active options were 22 calls and puts whose stock symbols have a single letter. It might not seem like a great investment strategy, but single-letter stocks...

AA : 24.81 (-9.22%)
C : 58.13 (-7.80%)
BAC : 34.39 (-7.60%)
D : 52.73 (-6.26%)
DDD : 1.8900 (-1.56%)
JPM : 210.28 (-8.05%)
ICF : 57.52 (-4.53%)
CCCC : 1.3100 (-4.73%)
NEE : 66.91 (-7.25%)
O : 55.15 (-3.35%)
C4 Therapeutics Appoints Steve Hoerter to Board of Directors to Strengthen Oncology Expertise

C4 Therapeutics appoints Steve Hoerter to its Board, enhancing oncology expertise to advance targeted protein degradation innovations.Quiver AI SummaryC4 Therapeutics, Inc. has announced the appointment...

CCCC : 1.3100 (-4.73%)
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

CCCC : 1.3100 (-4.73%)

Business Summary

C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. C4 Therapeutics...

See More

Key Turning Points

3rd Resistance Point 1.4633
2nd Resistance Point 1.4167
1st Resistance Point 1.3633
Last Price 1.3100
1st Support Level 1.2633
2nd Support Level 1.2167
3rd Support Level 1.1633

See More

52-Week High 8.0800
Fibonacci 61.8% 5.4786
Fibonacci 50% 4.6750
Fibonacci 38.2% 3.8714
Last Price 1.3100
52-Week Low 1.2700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades